Metformin and its use in chronic kidney disease,cardiovascular disease and cancer

Abstract

Metformin is nowadays considered to be the first-line pharmaceutical agent in type 2 diabetes mellitus (T2DM). When used as monotherapy, it can reduce the glycosylated haemoglobin (HbA_1c) level by up to 12 mmol/mol; a property that is not seen in many of the newer anti-diabetic agents. It also has the advantage of reducing the risk of cardiovascular disease in patients with T2DM when compared with sulfonylureas and insulin. Metformin is not recommended in patients with degrees of renal impairment and there is a lack of guidelines on the use of metformin in patients with stable chronic kidney disease.

Get full access to this article

View all access options for this article.

References

ADA. (2014). Standards of medical care in diabetes - 2014. Diabetes Care, 37(S1), S14–S80. doi: 10.2337/dc14-S014. Retrieved from http://care.diabetesjournals.org/content/37/Supplement_1/S14.full.pdf+html.

Bowker, S. L., Veugelers, P., Majumdar, S. R., & Johnson, J. A. (2006). Increased cancer-related morality for patients with type 2 diabetes who use sulphonylureas or insulin. Diabetes Care, 29(2), 254–258. doi:10.2337/diacare.29.02.06.dc05-1558.

Bruijstens

L. A.

van Luin

Buscher-Jungerhans

P. M. M.

Bosch

F. H.

(2008) Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment. The Netherlands Journal of Medicine 66(5): 185–190. Retrieved from www.njmonline.nl/getpdf.php?id=10000313.

Cavanaugh

K. L.

(2007) Diabetes management issues for patients with chronic kidney disease. Clinical Diabetes 25(3): 90–97. doi: 10.2337/diaclin.25.3.90.

Diabetes.co.uk. (2014). Guide to HbA1c. Retrieved from www.diabetes.co.uk/what-is-hba1c.html.

Dowling

R. J. O.

Goodwin

P. J.

Stambolic

(2011) Understanding the benefit of metformin use in cancer treatment. BioMedCentral Medicine 9: 33doi: 10.1186/1741-7015-9-33.

Herrington

W. G.

Levy

J. B.

(2008) Metformin: Effective and safe in renal disease? International Urology and Nephrology 40(2): 411–417. doi: 10.1007/s11255-008-9371-6.

Hirst

J. A.

Roberts

N. W.

Farmer

A. J.

Stevens

R. J.

Ali

(2012) Quantifying the effect of metformin treatment and dose on glycaemic control. Diabetes Care 35(2): 446–454. doi: 10.2337/dc11-1465.

Hosono

Endo

Takahaski

Sugiyama

Sakai

Uchiyama

Nakajima

(2010) Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prevention Research 3(9): 1077–1083. doi: 10.1158/1940-6207.CAPR-10-0186.

10.

Inoue

Iwasaki

Otani

Sasazuki

Noda

Tsugane

(2006) Diabetes mellitus and the risk of cancer: Results from a large-scale population-based cohort study in Japan. Archives of Internal Medicine 166(17): 1871–1877.

11.

Inzucchi

S. E.

Bergenstal

R. M.

Buse

J. B.

Diamant

Ferrannini

Nauck

Matthews

D. R.

(2012) Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6): 1364–1379. doi: 10.2337/dc12-0413.

12.

Kennedy

Herman

W. H.

(2005) Renal status among patients using metformin in a primary care setting. Diabetes Care 28(4): 922–924. doi: 102337/diacare.28.4.922.

13.

Klachko

Whaley-Connell

(2011) Use of metformin in patients with kidney and cardiovascular diseases. CardioRenal Medicine 1(2): 87–95. doi: 10.1159/000327151.

14.

Kwong

S.C.

Brubacher

(1998) Phenformin and lactic acidosis: A case report and review. The Journal of Emergency Medicine 16(6): 881–886. doi: 10.1016/S0736-4679(98)00103-6.

15.

Lipska

K. J.

Bailey

C. J.

Inzucchi

S. E.

(2011) Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 34(6): 1431–1437. doi: 10.2337/dc10-2361.

16.

NICE. (2009). Type 2 diabetes: The management of type 2 diabetes (partial update of CG87). Retrieved from www.nice.org.uk/CG87.

17.

Nye

H. J.

Herrington

W. G.

(2011) Metformin: The safest hypoglycaemic agent in chronic kidney disease? Nephron Clinical Practice 118(4): c380–c383. doi: 10.1159/000323739.

18.

Philbrick

A. M.

Ernst

McDanel

D. L.

Boss

M. B.

Moores

K. G.

(2009) Metformin use in renal dysfunction: Is a serum creatinine threshold appropriate? American Journal of Health-System Pharmacy 66(22): 2017–2023. doi: 10.2146/ajhp080330.

19.

Pilmore

(2010) Review: Metformin: Potential benefits and use in chronic kidney disease. Nephrology 15(4): 412–418. doi: 10.1111/j.1440-1797.2010.01328.x.

20.

Quinn

B. J.

Kitagawa

Memmott

R. M.

Gills

J. J.

Dennis

P. A.

(2013) Repositioning metformin for cancer prevention and treatment. Trends in Endocrinology and Metabolism 24(9): 469–480. doi: 10.1016/j.tem.2013.05.004.

21.

RCGP. Clinical example 3.17: Care of people with metabolic problems. Retrieved from www.rcgp.org.uk/∼/media/Files/GP-training-and-exams/Curriculum-2012/RCGP-Curriculum-3-17-Metabolic-Problems.ashx.

22.

Rizos

C. V.

Elisaf

(2013) Metformin and cancer. European Journal of Pharmacology 705(1–3): 96–108. doi: 10.1016/j.ejphar.2013.02.038.

23.

Rocha

Almeida

Santos

Carvalho

(2013) Metformin in patients with chronic kidney disease: Strengths and weaknesses. Journal of Nephrology 26(1): 55–60. doi: 10.5301/jn.5000166.

24.

Rojas, L. B. A., & Gomes, M. B. (2013). Metformin: An old but still the best treatment for type 2 diabetes. Diabetology & Metabolic Syndrome, 5, 6. doi: 10.1186/1758-5996-5-6.

25.

Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2010). Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, 3, art. no.: CD002967. doi: 10.1002/14651858.CD002967.

26.

Sharif

(2013) Metformin for patients with diabetes and concomitant renal restrictions-is there an evidence base? Quarterly Journal of Medicine: An International Journal of Medicine 106(3): 291–294. doi: 10.1093/qjmed/hct016.

27.

Solini

Penno

Bonora

Fondelli

Orsi

Trevisan

Renal Insufficiency and Cardiovascular Events Study Group. (2013) Age, renal dysfunction, cardiovascular disease and antihyperglycaemic treatment in type 2 diabetes mellitus. Journal of the American Geriatrics Society 61(8): 1253–1261. doi: 10.1111/jgs.12381.

28.

Sterner

Elmstahl

Frid

(2012) Renal function in a large cohort of metformin treated patients with type 2 diabetes mellitus. British Journal of Diabetes and Vascular Disease 12(5): 227–231. doi: 10.1177/1474651412459544.

29.

Stratton

I. M.

Adler

A. I.

Neil

H. A. W.

Matthews

D. R.

Manley

S. E.

Cull

C. A.

Holman

R. R.

(2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): A prospective observational study. British Medical Journal 321: 405–412. doi: 10.1136/bmj.321.7258.405.

30.

Summary of Product Characteristics. (2010). Glucophage 500 mg and 850 mg film coated tablets. Retrieved from www.medicines.org.uk/emc/medicine/1043.

31.

UKPDS Group. (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 352(9131): 854–865. doi: 10.1016/S0140-6736(98)07037-8.